R & D Days

Five Prime R & D Day December 2016

Five Prime R & D Day May 2015


Cabiralizumab (FPA008, CSF1R inhibitor antibody)

2017 American Society of Clinical Oncology (ASCO), June 2017

K. Kumar Sankhala et al.

POSTER: A Phase 1/2 Dose Escalation and Expansion Study of Cabiralizumab (FPA008), an anti-CSF1R antibody, in Tenosynovial Giant Cell Tumor (TGCT, Diffuse Pigmented Villonodular Synovitis D-PVNS)

2017 American Society of Clinical Oncology (ASCO), June 2017

Kamalesh S, et al.

ABSTRACT: Cabiralizumab PVNS ASCO 2017 Final Abstract

American Association for Cancer Research (AACR), April 2017

Bellovin D, et al.

POSTER: Antibody-Based Inhibition of CSF-1R as a Component of Combination Immunotherapy in Preclinical Models

American College of Rheumatology (ACR), November 2015

Zhou L, Sikorski R, et al.

POSTER: A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients with Rheumatoid Arthritis (RA): Preliminary Results

ABSTRACT: A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Subjects with Rheumatoid Arthritis (RA): Preliminary Results

Society for Immunotherapy of Cancer (SITC), November 2015

Bellovin D, Wondyfraw N, et al.

POSTER: cmFPA008, an Anti-Mouse CSF-1R Antibody, Combines with Multiple Immunotherapies to Reduce Tumor Growth in Nonclinical Models Poster

ABSTRACT: cmFPA008, an Anti-Mouse CSF-1R Antibody, Combines with Multiple Immunotherapies to Reduce Tumor Growth in Nonclinical Models

CRI-CIMT-EATI-AACR, September 2015

Brahmer J, Rasco D, et al.

POSTER: A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers Poster

ABSTRACT: A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers

American College of Rheumatology (ACR), November 2014

POSTER: A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results

Journal of Leukocyte Biology, September 2010

JOURNAL: Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells
Wei S, Nandi S, Chitu V, et al.
J Leukoc Biol
2010;88:495–505.

Science, May 2008

JOURNAL: Discovery of a Cytokine and Its Receptor by Functional Screening of the Extracellular Proteome
Lin H, Lee E, et al.
Science 9 May 2008: 807-811
DOI: 10.1126/science.1154370


FPA144 (anti-FGF receptor 2b antibody)

2017 American Society of Clinical Oncology (ASCO), June 2017

Catenacci, et al.

POSTER: Updated Antitumor Activity and Safety of FPA144, an ADCC-enhanced, FGFR2b Isoform-specific Monoclonal Antibody, in Patients with FGFR2b+ Gastric Cancer

2017 American Society of Clinical Oncology (ASCO), June 2017

Catenacci D, et al.

ABSTRACT: FPA144 ASCO 2017 Final Abstract

EORTC-NCI-AACR, December 2016

Ghoddusi M, Pierce K, et al.

POSTER: FGFR2b Represents a Novel Target for Treatment of Urothelial Cancer

American Society of Clinical Oncology (ASCO), June 2016

Lee J, Bendell J, et al.

PRESENTATION: Antitumor Activity and Safety of FPA144, an ADCC enhanced, FGFR2b Isoform-Selective Monoclonal Antibody, in Patients with FGFR2b+ Gastric Cancer and Advanced Solid Tumors

American Association for Cancer Research (AACR), April 2016

Pierce, K.

PRESENTATION: FPA144: A Therapeutic Monoclonal Antibody with Enhanced Antibody-Dependent Cell Killing for the Treatment of Fibroblast Growth Factor Receptor 2b Overexpressing Cancers

Powers J, Palencia S, et al.

POSTER: FPA144, a Therapeutic Monoclonal Antibody Targeting the FGFR2b Receptor, Promotes Antibody Dependent Cell-Mediated Cytotoxicity and Stimulates Sensitivity to PD-1 Blockade in the 4T1 Syngeneic Tumor Model in Mice

ABSTRACT: FPA144, a Therapeutic Monoclonal Antibody Targeting the FGFR2b Receptor, Promotes Antibody Dependent Cell-Mediated Cytotoxicity and Stimulates Sensitivity to PD-1 the 4T1 Breast Tumor Model in Mice

ASCO Gastrointestinal Cancers Symposium, January 2016

Bendell J, Rogers S, et al.

POSTER: FPA144-001: A First in Human Study of FPA144, an ADCC-enhanced, FGFR2b Isoform-selective Monoclonal Antibody in Patients with Advanced Solid Tumors

American Association for Cancer Research (AACR), April 2014

Gemo A, Deshpande A, et al.

POSTER: FPA144: A Therapeutic Antibody for Treating Patients with Gastric Cancers Bearing FGFR2 Gene Amplification


FP-1039 (FGF ligand trap)

European Society for Medical Oncology (ESMO) 2017 Congress, September 2017

Trigo, Jose et al.

ABSTRACT: Multicenter, Nonrandomized, Open-Label Phase 1b Study of FP-1039/GSK3052230 with Chemotherapy: Results in Malignant Pleural Mesothelioma (MPM)

POSTER: Multicenter, Nonrandomized, Open-Label Phase 1b Study of FP-1039/GSK3052230 with Chemotherapy: Results in Malignant Pleural Mesothelioma (MPM)

American Society of Clinical Oncology (ASCO), June 2016

Trigo J, van Brummelen E, et al.

POSTER: Multi-arm, open-label Phase 1b study of FP-1039/GSK3052230 with chemotherapy in malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) with deregulated fibroblast growth factor (FGF) pathway signaling: interim results in MPM

Annals of Oncology, December 2015

JOURNAL: A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors
Tolcher A, Papadopoulos K, et al.
Annals of Oncology 27: 526–532, 2016
doi:10.1093/annonc/mdv591 

World Conference on Lung Cancer, September 2015

Garrido P, Delgado I, et al.

ABSTRACT: FP1039/GSK3052230 with chemotherapy in patients with fibroblast growth factor (FGF)pathway deregulated squamous NSCLC or MPM

American Association for Cancer Research (AACR), April 2014

DeYoung M, Sherk C, et al.

POSTER: Preclinical efficacy of targeting FGF autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230

Bellovin D, Palencia S, et al.

POSTER: FP-1039/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC

Science Translational Medicine, March 2013

JOURNAL: Blockade of Nonhormonal Fibroblast Growth Factors by FP-1039 Inhibits Growth of Multiple Types of Cancer

Supplemental Materials
Harding, et al.
Sci Transl Med 27 March 2013:
Vol. 5, Issue 178, p. 178ra39

American Association for Cancer Research (AACR), April 2012

Harding T, Palencia S, et al.

POSTER: Preclinical efficacy of fibroblast growth factor ligand trap HGS1036 in lung carcinoma models with genomic amplification of FGFR1

EORTC-NCI-AACR, November 2010

Tolcher A, Papadopoulos K, et al.

POSTER: Preliminary Results of a Dose Escalation Study of the Fibroblast Growth Factor (FGF) “trap” FP-1039 (FGFR1:Fc) In Patients With Advanced Malignancies

American Society of Clinical Oncology (ASCO), June 2010

Keer H, Harding T, et al.

POSTER: Enrolling a Rare Patient Population: Establishing Proof of Concept for FP-1039,an FGF “Trap,” in Endometrial Cancer Patients with the S252W FGFR2 Mutation

American Association for Cancer Research (AACR), April 2010

Harding T, Palencia S, et al.

POSTER: Preclinical Effi cacy of FP-1039 (FGFR1:Fc) in Endometrial Carcinoma Models with Activating Mutations in FGFR2

AACR-EORTC-NCI, November 2009

Tolcher A, Papadopoulos K, et al.

POSTER: Preliminary Results of a Phase 1 Study of FP-1039 (FGFR1:Fc), A Novel Antagonist Of Multiple Fibroblast Growth Factor (FGF) Ligands, In Patients With Advanced Malignancies

American Association for Cancer Research (AACR), April 2009

Long L, Brennan T, et al.

POSTER: Preclinical Antitumor Efficacy of FP-1039, A Soluble FGF Receptor 1:Fc Conjugate, as a Single Agent or in Combination with Anticancer Drugs

AACR-NCI-EORTC, October 2007

Zhang H, Masuoka L, et al.

POSTER: FP-1039 (FGFR1:Fc), A Soluble FGFR1 Receptor Antagonist, Inhibits Tumor Growth and Angiogenesis

FPA150 (B7-H4 antibody)

European Society for Medical Oncology (ESMO) 2017 Congress, September 2017

Kaplan, Charles et al.

ABSTRACT:  FPA150, a Novel B7-H4 Therapeutic Antibody with Checkpoint Blockade and ADCC Activities

POSTER: FPA150, a Novel B7-H4 Therapeutic Antibody with Checkpoint Blockade and ADCC Activities

FPA154 (GITR agonist antibody)

American Association for Cancer Research (AACR), April 2017

Barbee S, et al.

POSTER: Development of FPA154, a novel tetravalent anti-GITR antibody, for the treatment of solid tumors

Society for Immunotherapy of Cancer (SITC), November 2016

Barbee S, Bellovin D, et al.

POSTER: Novel tetravalent anti-GITR antibody is a potent anti-tumor agent in vivo


Discovery Platform, Immuno-Oncology Research, and Respiratory Research

American Association for Cancer Research (AACR), April 2017

Brace A, et al.

POSTER: Identification Of Novel T Cell Co-inhibitory And Co-stimulatory Receptors From Screening A Comprehensive Library Of Extracellular Proteins

American Thoracic Society (ATS), May 2015

Zhu Y, Gosling J, et al.

POSTER: A High Content Screen to Identify Novel Factors That Restore Phagocytosis in COPD Alveolar Macrophages

Keystone Symposium, 2015

Sullivan K, Huang K, et al.

POSTER: An in vitro Co-culture Model to Characterize Cross-talk between COPD Airway Epithelia and Dendritic Cells

Society for Immunotherapy of Cancer (SITC), November 2014

Sallee N, Lee E, et al.

POSTER: Discovery of Novel Immune Checkpoint Regulators in a Comprehensive Library of Human Extracellular Proteins

Proceedings of the National Academy of Sciences (PNAS), September 2014

JOURNAL: Deorphanization of the human leukocyte tyrosinekinase (LTK) receptor by a signaling screen of the extracellular proteome
Zhang H, Pao L, et al.
www.pnas.org/cgi/doi/10.1073/pnas.1412009111

Combinatorial Chemistry & High Throughput Screening, February 2009

JOURNAL: Controlling Feature Selection in Random Forests of Decision Trees Using a Genetic Algorithm: Classification of Class I MHC Peptides.
Hansen L, Lee E, et al.
Combinatorial Chemistry & High Throughput Screening, 2009
Vol. 12, No. 5, 514-519

Drug Discovery Today, August 2006

JOURNAL: HTS Technologies in Biopharmaceutical Discovery
Ge Wu, Stephen K. Doberstein
Volume 11, Issues 15–16, August 2006, Pages 718–724
Drug Discovery Today, 11:15-16.


IO Research and Preclinical

Society for Immunotherapy of Cancer (SITC), November 2015

Sallee N, Karasyov A, et al.

POSTER: Identification of a Novel T Cell Co-Inhibitory Receptor and Potential Therapeutic Antibody Target in Oncology Poster

ABSTRACT: Identification of a Novel T Cell Co-Inhibitory Receptor and Potential Therapeutic Antibody Target in Oncology

Brennan T, Bellovin D, et al.

POSTER: Identification of Novel Immune Regulators of Tumor Growth Using RIPPS Screening in vivo Poster

ABSTRACT: Identification of Novel Immune Regulators of Tumor Growth Using RIPPS Screening in vivo